IMRX - NASDAQ
Immuneering Corporation
$4.55
+3.4%Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
At a Glance
Live SnapshotImmuneering Corporation Management Team
Mr. Harold E. Brakewood
Chief Business Officer
Compensation
$579,769
Mr. Michael D. Bookman J.D.
Chief Legal Officer & Secretary
Compensation
$689,959
Ms. Leah R. Neufeld
Chief People Officer
Dr. Brett M. Hall Ph.D.
Chief Scientific Officer
Compensation
$918,124
Mr. Robert J. Carpenter M.B.A., M.S.
Co-Founder & Chair Emeritus
Compensation
$45,000
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Co-Founder, President, Chief Executive Officer & Director
Compensation
$941,316
Ms. Paula George CPA
Director of Accounting & Operations and Assistant Corporate Controller
Dr. Peter King Ph.D.
Head of Discovery & Vice President
Dr. Praveen Nair Ph.D.
Head of Translational Pharmacology & Vice President
Ms. Mallory Morales CPA
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Immuneering Corporation Insider Positioning
During the last 12 months, insiders have purchased $1.15M worth of IMRX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
51.8K
234.34K
0
0.00
+234K
+$234K
6-9 Months
63.3K
211.46K
0
0.00
+211K
+$211K
9-12 Months
324.6K
703.37K
0
0.00
+703K
+$703K
Top Buyers
Feinberg Peter
Director
$352K
Schall Thomas J.
Director
$288K
Zeskind Benjamin J.
Director, 10 Percent Owner, Officer: President And Ceo
$85K
Hausman Diana
Director
$72K
Hall Brett Matthew
Officer: Chief Scientific Officer
$66K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.15M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
IMRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | April 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | April 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | May 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 21, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.